P-glycoprotein Mediated Interactions
P-glycoprotein is a drug efflux transporter that limits oral absorption and protects the brain. Inhibiting or inducing P-gp changes the pharmacokinetics of digoxin, DOACs, and many other drugs.
What Is P-glycoprotein?
P-glycoprotein (P-gp, also called MDR1 or ABCB1) is an ATP-dependent efflux transporter expressed in the intestinal epithelium, hepatic canalicular membrane, renal proximal tubule, and blood-brain barrier. It pumps substrates out of cells, reducing oral bioavailability, promoting biliary and renal excretion, and limiting brain penetration.
Clinical Significance
Many drug interactions attributed solely to CYP3A4 actually involve dual CYP3A4/P-gp inhibition, since the two systems share substantial substrate overlap and are often co-regulated. Understanding P-gp's independent contribution is important for drugs primarily cleared by this transporter.
Key P-gp Substrates
| Substrate | Clinical Impact of P-gp Changes |
|---|---|
| Digoxin | Narrow therapeutic index; small level changes cause toxicity |
| Dabigatran | Major P-gp substrate; bleeding or clotting risk |
| Edoxaban | P-gp substrate; dose adjustment required |
| Colchicine | P-gp + CYP3A4 substrate; fatal toxicity possible |
| Loperamide | P-gp keeps it out of the brain; inhibition causes CNS opioid effects |
| Cyclosporine | Dual CYP3A4/P-gp substrate |
| Topotecan, vincristine | Anticancer efficacy affected |
P-gp Inhibitors
Strong inhibitors:
- Cyclosporine, quinidine (prototype research inhibitor)
- Ritonavir, cobicistat
- Verapamil, dronedarone, ranolazine
- Itraconazole, ketoconazole
Moderate inhibitors:
- Amiodarone, clarithromycin, erythromycin
- Ticagrelor (clinically relevant with dabigatran)
Digoxin Example
Digoxin has a narrow therapeutic index (0.5-2.0 ng/mL) and is primarily renally cleared via P-gp. Adding amiodarone, verapamil, or quinidine inhibits renal P-gp-mediated digoxin secretion, increasing serum digoxin by 50-100%. Standard practice is to halve the digoxin dose when initiating these inhibitors and monitor levels.
Dabigatran Example
Dabigatran is the most P-gp-dependent DOAC. P-gp inhibitors increase dabigatran levels: dronedarone increases AUC by 70-100%. The FDA recommends reducing dabigatran dose to 75 mg twice daily with P-gp inhibitors in patients with moderate renal impairment, and contraindication with strong inhibitors when CrCl is below 30 mL/min.
P-gp Inducers
- Rifampin — reduces digoxin levels by 30%, dabigatran AUC by 66%
- St. John's wort — comparable induction; digoxin levels drop significantly
- Carbamazepine, phenytoin — moderate P-gp induction
Blood-Brain Barrier Implications
P-gp at the BBB limits CNS penetration of many drugs. Loperamide is a mu-opioid agonist that normally cannot enter the brain due to P-gp efflux. Co-administration with P-gp inhibitors (quinidine in research settings; inadvertent inhibition with massive doses) has caused respiratory depression and death, particularly in loperamide abuse scenarios.
Key Takeaways
- P-gp limits oral absorption, promotes excretion, and protects the blood-brain barrier
- Digoxin levels increase 50-100% with P-gp inhibitors; halve the dose and monitor
- Dabigatran is highly P-gp-dependent; dose adjustments or avoidance with inhibitors required
- Rifampin and St. John's wort induce P-gp, reducing substrate exposure
- P-gp inhibition at the BBB can allow opioid-like drugs (loperamide) into the brain